Summary: Axsome Therapeutics’ Q1 2024 report highlights advancements in its sleep medicine pipeline, with positive phase 3 results for AXS-12 in narcolepsy treatment and revenue …
Axsome Presents Q1 Results, Advances in Sleep Medicine Pipeline
Axsome